{"database": "press", "table": "releases", "rows": [["https://www.hawley.senate.gov/hawley-seeks-answers-about-data-used-in-fda-abortion-drug-study/", "Hawley Seeks Answers About Data Used in FDA Abortion Drug Study", "2026-10-09", "2026", "2026-10", "Republican", "Senate", "MO", "Josh Hawley", "H001089", "www.hawley.senate.gov", "hawley", "https://www.hawley.senate.gov/press-releases/page/", "scraper", "WASHINGTON \u2014 Today, U.S. Senator Josh Hawley (R-Mo.) sent a letter to Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas raising concerns that the FDA\u2019s long-promised safety study of the abortion drug mifepristone may be using incomplete data. The letter raises questions about whether the study can adequately assess the effect of the Biden Administration\u2019s 2023 Risk Evaluation and Mitigation Strategy(REMS)\u2014which removed important safeguards\u2014and whether the FDA is reviewing all relevant data in its effort to complete the study.\n\n\u201cI write with concern that FDA\u2019s long-promised safety study of the abortion drug mifepristone may be using incomplete data. On October 7, the Department of Justice filed a status report on FDA\u2019s behalf in Louisiana v. FDA, the litigation challenging FDA\u2019s 2023 removal of the in-person dispensing requirement for mifepristone during the Biden Administration. According to the filing, FDA\u2019s safety study of the drug relies in part on \u2018a variety of data sources contained within Sentinel,\u2019 the agency\u2019s distributed database of insurance claims and health records. Yet the filing does not provide the time horizon for its source data. To ensure credibility, FDA must confirm its review includes data from the period after the Biden Administration gutted safety regulations in 2023,\u201d wrote Senator Hawley.\n\nHe continued, \u201cAs you know, in April 2021, FDA announced that it would not enforce its in-person dispensing requirement for mifepristone during the COVID-19 public health emergency. And on January 3, 2023, it formally modified the mifepristone REMS (Risk Evaluation and Mitigation Strategy) to eliminate in-person dispensing and to allow certified retail pharmacies to dispense the drug. Louisiana and other states have challenged that 2023 decision in court.\u201d\n\n\u201cFDA\u2019s confirmed reliance on Sentinel data, along with ambiguity as to whether FDA acquired other commercially available data, raises questions about whether FDA\u2019s study can adequately assess the impact of the Biden Administration\u2019s 2023 REMS. According to the Sentinel Initiative, the date range of available data varies by source. For example, the end date of Sentinel\u2019s Medicaid data appears to be 2021\u2014leading to a nearly 50 percent drop in database enrollment after that year\u2014while data from 2024 \u2018and possibly 2023\u2019 appear incomplete from publicly available sources.\u201d Senator Hawley asserted.\n\nRead the full letter here or below.\n\nThe Honorable Kyle Diamantas\n\nActing Commissioner of Food and Drugs\n\nU.S. Food and Drug Administration\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nDear Acting Commissioner Diamantas:\n\nI write with concern that FDA\u2019s long-promised safety study of the abortion drug mifepristone may be using incomplete data. On October 7, the Department of Justice filed a status report on FDA\u2019s behalf in Louisiana v. FDA, the litigation challenging FDA\u2019s 2023 removal of the in-person dispensing requirement for mifepristone during the Biden Administration. According to the filing, FDA\u2019s safety study of the drug relies in part on \u201ca variety of data sources contained within Sentinel,\u201d the agency\u2019s distributed database of insurance claims and health records.[1] Yet the filing does not provide the time horizon for its source data. To ensure credibility, FDA must confirm its review includes data from the period after the Biden Administration gutted safety regulations in 2023.\n\nAs you know, in April 2021, FDA announced that it would not enforce its in-person dispensing requirement for mifepristone during the COVID-19 public health emergency. And on January 3, 2023, it formally modified the mifepristone REMS (Risk Evaluation and Mitigation Strategy) to eliminate in-person dispensing and to allow certified retail pharmacies to dispense the drug. Louisiana and other states have challenged that 2023 decision in court. A recent independent study has shown that nearly 11% of women have suffered a serious adverse health event within 45 days of using mifepristone.[2]\n\nFDA\u2019s confirmed reliance on Sentinel data, along with ambiguity as to whether FDA acquired other commercially available data, raises questions about whether FDA\u2019s study can adequately assess the impact of the Biden Administration\u2019s 2023 REMS. According to the Sentinel Initiative, the date range of available data varies by source. For example, the end date of Sentinel\u2019s Medicaid data appears to be 2021\u2014leading to a nearly 50 percent drop in database enrollment after that year\u2014while data from 2024 \u201cand possibly 2023\u201d appear incomplete from publicly available sources.[3]\n\nCompounding the uncertainty, FDA\u2019s filing states that its study confirmed adequate exposures and outcomes \u201cacross relevant time periods,\u201d but it never identifies those periods.[4] This suggests that if the agency primarily relies on data from Sentinel, its analysis may rest largely on procedures that occurred before the 2023 REMS took effect and possibly exclude analysis of a large Medicaid population after that date. If the FDA\u2019s review does not capture this population, the study may not properly inform the agency\u2019s analysis about whether to modify the REMS by excluding women who have received the drug by mail. Other commercially available data from all-payer claims could help fill the gap left by Sentinel\u2019s time-limited Medicaid data. Yet according to the DOJ status report, while the FDA \u201ccontinues to gather and analyze additional data\u201d outside Sentinel, it does not say what those datasets are or even what years they cover.[5]\n\nTo resolve these issues and provide assurance to patients that FDA is reviewing all relevant data, please answer the following questions in writing by October 22, 2026:\n\nDoes the FDA\u2019s Sentinel database include all data after 2021 or 2023, such as that of the Medicaid population?\n\nHas the FDA sought to acquire this data? If not, why not?\n\nIdentify the \u201cadditional data\u201d outside Sentinel that FDA is gathering and analyzing, and the precise period each source covers.\n\nDid the FDA originally plan to acquire a broader set of insurance data? If so, when and why did the agency change to reviewing primarily Sentinel data?\n\nThank you for your prompt attention to this request.\n\nSincerely,", 1, "2026-10-10T10:59:13Z", "2026-10-10T11:00:38Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.hawley.senate.gov/hawley-seeks-answers-about-data-used-in-fda-abortion-drug-study/"], "units": {}, "query_ms": 0.7500930223613977, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}